Shao, Guoliang

Zhejiang Cancer Hospital

1 paper on CoChatORCID 0009-0009-6962-7358

Most cited papers

Verified
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
Ren, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., Li, Q., Lu, Y., Chen, Y., Guo, Y., et al. (2021) · The Lancet Oncology
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 1,124

Go further with a free account

Verify every reference, keep papers in a library, and ask questions across them.

Sign up - it is free